Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V3-MOMMO
- Development stage
- Phase 2
- Lead developer
- Immunitor
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
V3-MOMMO is an experimental oral immunotherapy developed by Immunitor for the treatment of breast cancer. The drug is a tableted preparation composed of hydrolyzed and heat-inactivated components derived from the blood and tumor tissues of breast cancer patients. It is designed to act as a therapeutic vaccine, leveraging the presence of tumor-associated antigens to stimulate a systemic immune response against the malignancy. This approach follows Immunitor's platform of using blood-derived antigens for oral delivery, which has been investigated in other indications such as hepatocellular carcinoma and various infectious diseases.
Beyond the preview
Go deeper on V3-MOMMO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V3-MOMMO.